Dr. Gill reviews the advantages and challenges of using the newly approved recombinant von WIllebrand factor replacement product in clinical practice.
Joan C. Gill, MD: New Recombinant Factors for von Willebrand Disease
Recent Articles
Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment
Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related mortality in patients with cancer, according to results from...
New Tool Provides Simple Approach to Pausing Direct Oral Anticoagulants for Surgery
Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) scheduled...
PERIOP 2: Do Patients at High Risk for Arterial Thromboembolism Need LMWH Bridging?
Michael Kovacs, MD, discusses results from the PERIOP 2 trial, which found that post-procedure bridging with low-molecular weight heparin during warfarin interruption offered no...
A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes
Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.
Good News on the HORIZON: Melflufen Induces Response in Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) that was refractory to pomalidomide and/or daratumumab responded to treatment with melflufen, according to interim results...
Current Issue
December 2018, Volume 4, Issue 14
This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.
